Stay updated on Pemigatinib Dose-Escalation Clinical Trial
Sign up to get notified when there's something new on the Pemigatinib Dose-Escalation Clinical Trial page.

Latest updates to the Pemigatinib Dose-Escalation Clinical Trial page
- Check4 days agoChange DetectedThe page now presents the FIGHT-101 pemigatinib clinical trial record, including its study design, eligibility criteria, locations, outcome measures, publications, and study documents.SummaryDifference100%

- Check11 days agoChange DetectedThe footer revision number changes from v3.7.2 to v3.8.0, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check18 days agoNo Change Detected
- Check25 days agoChange DetectedA general NIH notice about the transition from “Artificial Intelligence” to “Super Intelligence” appears above the page, and the site revision identifier changes from v3.7.1 to v3.7.2. The study record remains inaccessible behind a 403 error.SummaryDifference1%

- Check39 days agoChange DetectedThe footer’s site revision identifier changed from v3.7.0 to v3.7.1, while the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check53 days agoChange DetectedThe page now displays a 403 Forbidden error instead of the study details, blocking access to the study record and related documents. This change changes the page’s usability by preventing access to its primary content.SummaryDifference25%

- Check60 days agoChange DetectedRevision tag updated from v3.6.6 to v3.7.0. This represents a backend/template update and does not alter the study details shown on the page.SummaryDifference0.0%

Stay in the know with updates to Pemigatinib Dose-Escalation Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Pemigatinib Dose-Escalation Clinical Trial page.